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Many chronic fatigue syndrome (CFS) and fibromyalgia syndrome (FMS) patients (35–68%)
use nutritional supplements, while it is unclear whether deficiencies in vitamins and minerals
contribute to symptoms in these patients. Objectives were (1) to determine vitamin and min-
eral status in CFS and FMS patients as compared to healthy controls; (2) to investigate the
association between vitamin and mineral status and clinical parameters, including symptom
severity and quality of life; and (3) to determine the effect of supplementation on clinical
parameters.
Methods
The databases PubMed, EMBASE, Web of Knowledge, and PsycINFO were searched for
eligible studies. Articles published from January 1st 1994 for CFS patients and 1990 for FMS
patients till March 1st 2017 were included. Articles were included if the status of one or more
vitamins or minerals were reported, or an intervention concerning vitamins or minerals was
performed. Two reviewers independently extracted data and assessed the risk of bias.
Results
A total of 5 RCTs and 40 observational studies were included in the qualitative synthesis, of
which 27 studies were included in the meta-analyses. Circulating concentrations of vitamin
E were lower in patients compared to controls (pooled standardized mean difference
(SMD): -1.57, 95%CI: -3.09, -0.05; p = .042). However, this difference was not present
when restricting the analyses to the subgroup of studies with high quality scores. Poor study
quality and a substantial heterogeneity in most studies was found. No vitamins or minerals
have been repeatedly or consistently linked to clinical parameters. In addition, RCTs testing
supplements containing these vitamins and/or minerals did not result in clinical
improvements.
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Discussion
Little evidence was found to support the hypothesis that vitamin and mineral deficiencies
play a role in the pathophysiology of CFS and FMS, and that the use of supplements is
effective in these patients.
Registration
Study methods were documented in an international prospective register of systematic
reviews (PROSPERO) protocol, registration number: http://www.crd.york.ac.uk/
PROSPERO/display_record.asp?ID=CRD42015032528.
Introduction
Chronic fatigue syndrome (CFS) and fibromyalgia syndrome (FMS) are syndromes of
unknown origin. The core symptom of CFS is profound disabling fatigue [1], whereas FMS is
characterized by chronic widespread pain [2,3]. CFS and FMS are known for substantial clini-
cal and diagnostic overlap, for example, chronic pain and fatigue are common in both patient
groups. The two syndromes are often comorbid; up to 80% of CFS patients reported a history
of clinician-diagnosed FMS [4,5]. This has resulted in the hypothesis that these syndromes
share etiological pathways [6].
Vitamin and mineral deficiencies may play a role in the pathophysiology of both CFS and
FMS, although mechanisms behind this hypothesis are not entirely clear [7,8]. In addition,
results of studies investigating the effects of nutritional supplementation or dietary intake on,
for example, symptom severity in these patient groups, are conflicting [9–12]. Nevertheless, a
large proportion of CFS and FMS patients indicate they use nutritional supplements (35%-
68%) [10,13–15], compared to the Dutch general population (27–56%) [16]. The higher nutri-
tional supplement use among patients may be due to encouragements by specialty stores, the
internet or (complementary medicine) clinics. Vitamins and minerals in these products are
sometimes supplemented in doses high enough to cause health problems, for example gastric
discomfort, insomnia, dizziness and weakness [17]. More information is needed on the evi-
dence for (marginal) vitamin and mineral deficiencies in CFS and FM, and the potential bene-
fits in taking nutritional supplements.
Recently, a review investigating hypovitaminosis D in both chronic pain and FMS patients
showed that these patients were at significantly higher risk of hypovitaminosis D than healthy
controls [18]. Unfortunately, further reviews on vitamin and mineral deficiencies among CFS
and FMS patients are lacking. We therefore carried out this first systematic review on vitamin
and mineral status in CFS and FMS. We explored the following research questions: first, what
is the evidence for deficiencies in vitamin and mineral status in CFS and FMS patients as com-
pared to healthy controls? Second, is vitamin and mineral status associated with clinical
parameters, including symptom severity and quality of life, in CFS and FMS? Third, what is
the evidence for an effect of vitamin and mineral supplementation, as compared to placebo, on
clinical parameters in CFS and FMS patients? Because it is currently unknown whether CFS
and FMS result from the same etiology, we analyzed results both for the combined and for the
separate syndromes.
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Methods
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines (S1 Table) [19]. Prior to start of article inclusion, we documented study
methods in an international prospective register of systematic reviews (PROSPERO) protocol,
registration number: CRD42015032528, http://www.crd.york.ac.uk/PROSPERO/display_
record.asp?ID=CRD42015032528.
Data sources and searches
The databases PubMed, EMBASE, Web of Knowledge, and PsycINFO were systematically
searched. Articles published between January 1st 1994 and 1990, for CFS and FMS respectively,
and March 1st 2017 were included. We focused on the most recent diagnostic guidelines,
namely the International Center of Disease Control (CDC) diagnostic criteria for CFS that was
established in 1994 [1], and the American College of Rheumatology (ACR) criteria for FMS in
1990 [2]. To retrieve relevant articles from PubMed, we formulated a search string (S1 Appen-
dix) that consisted of CFS, FMS, and synonyms, vitamins, minerals, micronutrients and syno-
nyms, while excluding systematic reviews or animal studies. This search string was adapted
according to the thesaurus of the databases EMBASE, Web of Knowledge, and PsycINFO. All
included studies were screened for potential references that were not included in the first
search. Duplicates were removed, as well as studies including pediatric participants. There
were no language restrictions; included non-English articles were translated (French, Italian,
Polish, and Turkish articles) by native speakers.
Study selection
Title and abstract were screened by two independent reviewers (M.L.J. and I.M.) for the fol-
lowing criteria: (1) CFS or FMS patients; (2) vitamin or mineral status; and (3) study design.
Studies which were in agreement with the eligibility criteria were retrieved as full text. Discrep-
ancies between the two researchers were resolved by consensus, and when needed a third
assessor was consulted (J.G.M.R.). Reasons for exclusion and percentage of agreement, as
Cohen’s kappa, between the assessors were documented.
Participants of the included studies had to be adults (i.e.18 years) suffering from CFS or
FMS according to the official diagnostic criteria [1–3]. Studies that involved patients with a
combination of CFS and FMS or other comorbid medical conditions were excluded. Further-
more, the vitamin or mineral status had to be assessed or reported in the article, or there had
to be an intervention concerning vitamins or minerals. Patients were compared with healthy
controls in observational studies, or vitamin and mineral supplementation were compared
with placebo in intervention studies. Lastly, cross-sectional studies comparing cases and con-
trols, cohort studies and randomized controlled trials (RCTs) were included. Case reports,
clinical cohorts without appropriate controls (e.g. controls with musculoskeletal pain or
fatigue), (systematic) reviews, expert opinion, and other study designs were excluded.
Data extraction
Two reviewers (M.L.J. and I.M.) independently extracted data and assessed the risk of bias for
each study. The first ten articles were screened together to pilot the data extraction and risk of
bias form. Reasons for exclusion and percentage of agreement between the assessors were
documented.
From the included articles, the following information was extracted: name first author, pub-
lication year, type FSS, number and age of the participants, and vitamin or mineral status. In
Vitamins and minerals in chronic fatigue syndrome and fibromyalgia syndrome
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addition, data on smoking habits or alcohol use, diet (and assessment tool used), BMI (or
waist circumference, waist-hip ratio), physical activity (assessment tool), socioeconomic status,
ethnicity, severity of illness (assessment tool), duration of illness, co-morbidities (somatic and
psychiatric), medication use, clinical parameters including symptom severity and quality of
life, and in case of RCTs the relevant co-intervention(s) were also extracted.
Quality assessment
To assess quality of RCTs, the Cochrane Collaboration’s tool for assessing risk of bias was
employed [20]. For observational studies, literature indicates lack of a single methodological
assessment tool [21,22]. Therefore, we adjusted a previously developed quality tool for obser-
vational studies in this field [23], for use in studies that focus specifically on the association
between vitamin and mineral status and CFS or FMS. Eight of the nine items in this original
quality tool originated from guidelines or tools for either reporting or appraising observational
research [24–26]. These items were adjusted to the specific question on vitamins and minerals
and classified into three key domains: appropriate selection of participants (validated disorder,
representative controls, in- and exclusion criteria, disease characteristics), appropriate quanti-
fication of vitamin and mineral status (duplicate quantification, appropriate outcome), and
appropriate control for confounding (assessed confounders, analyses adjusted). The item: “Is
the assessor blind for disease status”, was excluded since from the original quality tool since it
is not applicable in the current review. Furthermore, we added the item “Are methods for
assessment of vitamin and mineral status clearly stated”, based on the adapted Newcastle
Ottawa scale for cross-sectional studies (S2 Appendix) [27]. RCTs that contained relevant
observational data (n = 4/5), were assessed with both the Cochrane tool and the observational
studies quality tool. For both quality tools, items were rated as (0) low risk, (1) medium risk,
and (2) high risk of bias. The maximum attainable quality score was 14 for RCTs, and 18 for
observational studies.
Data synthesis and analysis
We first constructed an overview of available data on the different vitamins and minerals.
Characteristics of the included studies were systematically listed to generate a clear overview of
the current literature on vitamins and minerals in CFS and FMS patients. For those vitamins
and minerals with more than five studies available, we did quantitative syntheses on aggre-
gated data. For these syntheses, data was pooled with the random effects model of meta-
analysis, using Stata statistical software, version 14 (Statacorp LP, Texas). To allow pooling
across studies that used different outcomes of vitamin or mineral plasma or serum levels, we
calculated the standardized mean difference (SMD). For proportions of deficiencies, the odds
ratio (OR) was calculated and pooled. Subsequently, the SMD and OR for each study were
weighted by their inverse variance and the corresponding 95%CI were calculated. The exis-
tence of heterogeneity among studies was assessed by Q-tests, and the degree of the heteroge-
neity was quantified by calculating the I-squared (I2) value. Publication bias was inspected
visually by a funnel plot, and an Egger’s test was conducted to quantify funnel plot asymmetry
[28]. The Tweedie’s Trim and Fill test was performed as an additional sensitivity analysis to
identify and correct for funnel plot asymmetry arising from publication bias [29]. When the
Trim and Fill test was performed, and additional studies were added to the analyses, contour-
enhanced funnel plots were used instead of regular funnel plots to examine whether asymme-
try in the funnel plots was due to publication bias [30]. Subgroup analyses were performed
including studies with more than half of the maximum study quality score (>9 quality points),
if more than three studies with a sufficient quality score were available. Furthermore, vitamin
Vitamins and minerals in chronic fatigue syndrome and fibromyalgia syndrome
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and mineral status of CFS and FMS patients were investigated separately if more than three
studies were available. Findings were considered statistically significant if P<0.05.
Results
Study inclusion
Results of the systematic review and meta-analysis are presented in a flow diagram (Fig 1).
Cohen’s kappa’s for the abstract and full text selection were 0.96 and 0.89 respectively, indicat-
ing very good consistency of agreement [31]. Out of 108 studies included for the full text
review, 45 studies were included in the current review.
Characteristics of the included studies are presented in Table 1, and results of the quality
assessment in Tables 2 and 3. Most studies involved FMS patients (n = 35/45); 4 of the 5 RCTs
also contained relevant observational data. Vitamin and mineral status was mainly assessed in
plasma or serum (n = 40/45). Furthermore, quality scores revealed poor study quality (i.e.
equal or less than half of the maximum study quality score) in the vast majority of observa-
tional studies (n = 27/44; range 4–14 points) and RCTs (n = 3/5; range 5–12 points). Only few
observational studies defined all described in- and exclusion criteria for the investigated popu-
lation, including medication use, somatic morbidity, and psychiatric morbidity (n = 10/44).
The CFS or FMS diagnostic criteria were often described in observational studies, but
researchers failed to state whether or not the syndromes were diagnosed by a physician
(n = 40/44). Disease characteristics were frequently not fully presented (n = 15/44), or were
completely absent (n = 18/44) in observational studies. Almost all observational studies did
not assess vitamin or mineral in duplicate (n = 38/44). Most studies that assessed vitamin or
mineral status did not clearly state the methods for assessment of vitamin and mineral status
(n = 27/44). Furthermore, most observational studies did not adjust their analyses for any
potential confounders (n = 43/44). Lastly, most RCTs had a medium to high risk of bias for
random sequence generation (n = 3/5), allocation concealment (n = 3/5), blinding of outcome
assessment (n = 4/5), incomplete data (n = 4/5), selective reporting quantification (n = 3/5),
and other bias (n = 5/5).
Systematic review
Studies that were not included in the meta-analyses are presented in Table 4.
Interventions. Five RCTs were included. The first RCT determined the effect of magne-
sium citrate treatment in combination with amitriptyline versus amitriptyline only, on FMS
symptoms, over a period of 8 weeks [34]. They found that amitriptyline and magnesium sup-
plementation was more effective on all measured outcomes than amitriptyline alone. The sec-
ond RCT investigated the effect of a polynutrient supplement (containing several vitamins
(including A, B, C, D, E), minerals (including calcium, magnesium) and (co)enzymes), on
fatigue and physical activity of patients with CFS, over a period of 10 weeks [37]. They found
no significant difference between the placebo and treatment group on any of the outcome
measures. A third RCT examined vitamin C and E treatment combined with exercise versus
exercise only, in FMS patients, over a period of 12 weeks [57]. Although both interventions
lead to significantly higher vitamin A, C, and E serum levels, the FMS symptoms did not
improve in both groups. Furthermore, the most recent RCT investigated the effect of vitamin
D, on symptoms in CFS patients, over a period of 6 months [75]. Despite a statistically signifi-
cant increase in vitamin D, they found no evidence of improvement in symptoms of fatigue or
depression. Lastly, in the fifth RCT, cholecalciferol was administered for 20 weeks in FMS
patients, with the dosage depending on patients calcifediol levels [74]. A significant treatment
effect on intensity of pain was found in the treatment group versus placebo. No changes in
Vitamins and minerals in chronic fatigue syndrome and fibromyalgia syndrome
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somatization, depression and anxiety, physical and mental health, and FMS symptom severity
were observed in both the treatment and placebo group.
Clinical parameters. All studies investigating vitamin A (n = 1) [67], vitamin C (n = 1)
[67], ferritin (n = 2) [50,62], iron (n = 1) [50], and selenium (n = 1) [69], found no significant
Fig 1. Flow diagram.
https://doi.org/10.1371/journal.pone.0176631.g001
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associations between vitamin and mineral status and clinical parameters in FMS patients
(Table 3). Most studies investigating vitamin D (n = 6) found no significant associations
between vitamin D and clinical parameters in CFS [75] and FMS [35,49,65,72,76] patients.
However, two studies found significantly higher VAS-score for pain in patients with vitamin
D levels <30 ng/ml compared to FMS patients with vitamin D levels of>30ng/ml [44,60]. Sig-
nificant negative associations were found for vitamin E in plasma and fatigue in CFS patients
(n = 1/2) [73], and serum and erythrocyte magnesium and fibromyalgia symptoms (n = 1/3)
[34]. A significant positive association was found for serum zinc and somatic symptoms in
fibromyalgia patients (n = 1/3) [48].
Vitamin and mineral status. All studies that investigated vitamin B12 (n = 1) [62], folic
acid (n = 1) [62], iron (n = 2) [48,50], molybdenum (n = 1) [66], phosphorus (n = 4)
[46,49,61,71,72] sodium (n = 3) [42,46,66], and iodine (n = 1) [66], and the majority of studies
that investigated potassium (n = 3/4) [42,46,59], and selenium status (n = 4/5) [39,46,66,69]
found no statistically significant difference between patients and controls (Table 3). In con-
trast, all studies that investigated vitamin B1 (n = 1/1) [54], and manganese (n = 1/1) [46], and
the majority of studies that investigated vitamin A (n = 2/4) [39,67], found statistically signifi-
cant lower serum values in patients versus controls. The majority of the studies that were not
suitable for inclusion in the meta-analyses reported significantly lower vitamin E in patients
versus controls (n = 3/4) [55,56,73]. Statistically significant results were found in the majority
of the included studies investigating copper (n = 3/4) [46,48,66], ferritin (n = 4/5)
[46,50,62,66], and zinc (n = 5/7) status [48,51,66,69]. However, the direction of the differences
was equivocal for all three minerals: levels of copper were higher among patients in 3 studies
and lower in 1, levels ferritin were higher among patients in 2 studies and lower in 2, and levels
of zinc were lower in 3 studies and higher in 2.
Meta-analysis
Vitamin C, vitamin D, vitamin D deficiency (<20ng/ml), vitamin E (Fig 2), and the minerals
calcium, and magnesium status, and were reported in more than five studies and were there-
fore investigated using meta-analysis (Fig 3). Meta-analysis revealed that circulating





































Total score mean (SD): 10.0 (2.6)
According to the Cochrane Collaboration’s tool.
white = low risk, light gray = medium risk, dark gray = high risk
https://doi.org/10.1371/journal.pone.0176631.t003
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Table 4. Vitamin and mineral status in the included studies.
Vitamin A
Study Patients Controls Statistically
significant
Linked to clinical parameter
Mean SD Mean SD
Akkus et al, 2009 [32] 0.30 μmol/l 0.10 0.45 0.16 p<.01 NR
Eisinger et al, 1997
[39]
2.7 μmol/l 1.5 2.3 0.9 NS NR
Nazıroğlu et al, 2010
[57]
1.5 μmol/l 0.5 2.4 0.2 p<.05 NR
Sakarya et al, 2011
[67]
1.46 mmol/l 0.47 1.25 0.26 NS FIQ Pearson’s correlation coefficient:
-0.083 (NS)
Vitamin B1
Mechtouf et al, 1998
[54]
58 ng/ml 38.9 49.6 14.8 p<.05 NR
Vitamin B12
Ortancil et al, 2010
[62]
297.6 pg/ml 120.7 295.7 113.0 NS NR
Vitamin C
Sakarya et al, 2011
[67]
x x x x x FIQ Pearson’s correlation coefficient:
-0.115 (NS)
Vitamin D
Al-Allaf et al, 2003 [33] <20nmol/l (n (%)): 18 (45) n (%): 7 (18.9%) p<0.015 NR
Baygutalp et al, 2014
[35]
x x x x x FIQ Spearman correlation: 0.231 (NS)
Kasapoğlu Aksoy
et al, 2016 [44]
x x x x x <30 ng/ml vs >30 ng/ml in FMS:
VAS pain: 8.4 (1.6) vs 6.7 (2.0) p = .002
FIQ: 65.4 (12.0) vs 57.2 (16.1) p = .088
Maafi et al, 2016 [49] x x x x x FIQR Spearman correlation: -0.093 (NS)
Number of tender points: -0.194 (NS)
VAS pain: -0.097 (NS)
Okyay et al, 2016 [60] x x x x x <20 ngl/ml vs 20–30 vs >30 ng/ml in FMS:
FIQ: 56.6 (8.9) vs 48.8 (2.8) vs 41.4 (8.2)
p = .000
VAS pain: 7.4 (1.4) vs 6.4 (0.5) vs 5.1
(1.0) p = .000
FIQ Spearman correlation: -0.621 (p =
.000)
VAS pain Spearman correlation: -0.578 (p
= .000)
Study Patients Controls Statistically
significant
Linked to clinical parameter
Mean SD Mean SD
Rezende Pena et al,
2010 [65]
x x x x x Number of tender points Pearson’s
correlation coefficient: -0.160 (NS)
VAS pain: -0.196 (NS)
Ulusoy et al, 2010 [72] <20ng/l (n (%)): 26 (86.7) n (%): 29 (96.7) NS FIQ Pearson’s correlation coefficient:
0.071 (NS)
Wepner et al, 2014 [74] 19.94 ng/ml 6.066 NR NR NR NR
Witham et al, 2015 [75] 44 and 48 nmol/l 15 and 20 NR NR NR Piper fatigue scale: no improvement after
vitamin D3 treatment
Yildirim et al, 2016 [76] x x x x x FIQ Pearson’s correlation coefficient:
r = 0.112 (NS)
VAS pain: r = 0.104 (NS)
Vitamin E
Kurup et al, 2003 [47] 5.22 μg/ml RBC 0.31 5.25 0.33 NS NR
Miwa et al, 2010 [55] 2.81 mg/g lipids 0.73 3.88 0.65 p<.001 NR
(Continued )
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Table 4. (Continued)
Miwa et al, 2008 [56] 3.03 mg/g lipids 0.72 3.78 0.66 p<.001 NR
Sakarya et al, 2011
[67]
x x x x x FIQ Pearson’s correlation coefficient:
−0.171 (NS)
Vecchiet et al, 2002
[73]
9.5 μmol/mg LDL 1.0 18.0 1.5 p<.001 Linear regression analyses fatigue versus
vitamin E in plasma:
Y = 56.674–0.4467X
r = -0.6098 (p < 0.004)
Calcium
Bazzichi et al, 2008
[36]
231.0 nM platelet 13.75 (SEM) 198.3 10.40 NS NR




p = .001 NR
Ng et al, 1999 [58] 2288.4 μg/g hair 1486.2 846.3 645.7 p = .025 NR















Khalifa et al, 2016 [45] 145.8 μg/dl 17.34 116.50 14.35 p<.05 NR




p = .029 NR
La Rubia et al, 2013
[48]
105.99 mg/dl 17.03 83.55 9.20 p<.001 NR
Study Patients Controls Statistically
significant
Linked to clinical parameter
Mean SD Mean SD





















p = .007 NR
La Rubia et al, 2013
[48]
52.33 g/dl 15.07 57.42 17.01 NS NR
Mader et al, 2012 [50] 63.68 ng/ml





46.24 p = .18
p<.04
FIQ Spearman correlation: NS
Ortancil et al, 2010
[62]
27.3 ng/ml





30.8 p = .035
p = .001
FIQ Spearman correlation: NS
Rosborg et al, 2007
[66]
422 mg/l (median) 245–585
(range)
400 273–465 p = .046 NR
Folic acid
Ortancil et al, 2010
[62]
9.2 ng/ml 3.1 8.9 2.5 NS NR
Iodine


















La Rubia et al, 2013
[48]
81.82 mg/dl 34.64 83 30.07 NS NR
Mader et al, 2012 [50] 82.32 μg/dl 32.75 75.31 29.13 NS FIQ Spearman correlation: NS
(Continued )
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Table 4. (Continued)
Magnesium







0.36 p<.001 FIQ Pearson’s correlation serum Mg:
-0.426 (p<.001)
Erythrocyte Mg:
-0.309 (p = .013)
Bazzichi et al, 2008
[36]
1.30 mM platelet 0.079 (SEM) 1.07 0.056 p = .02 NR




0.24 2.39 0.24 NS NR




1.7 3.9 1.3 NS NR
Kim et al, 2011 [46] 52 μg/g 25–107 (95%
CI)
72 36–147 p = .008 NR
Study Patients Controls Statistically
significant
Linked to clinical parameter
Mean SD Mean SD
McCully et al, 2005
[53]
0.47 mM muscle 0.07 0.36 0.06 p<.01 NR
Ng et al, 1999 [58] 84.7 μg/g hair 73.3 46.8 28.9 p = .05 NR














Sakarya et al, 2011
[67]
x x x x x FIQ Pearson’s correlation coefficient:
0.014 (NS)
Sendur et al, 2008 [69] x x x x x FIQ Pearson’s correlation coefficient:
-0.040 (NS)
Manganese
Kim et al, 2011 [46] 140 ng/g 80–260 (95%
CI)
190 80–480 p = .029 NR
Molybdenum
Rosborg et al, 2007
[66]
0.6 μg/l (median) <0.25–4.4
(range)
0.6 <0.25–5.7 NS NR
Phosphorus
Kim et al, 2011 [46] 146 μg/g 116–183
(95%CI)
143 116–176 NS NR
Maafi et al, 2016 [49] 3.6 mg/dl 0.47 3.66 0.54 NS NR
Olama et al, 2013 [61] 3.55 mg/dl 0.12 3.6 0.16 NS NR
Tu¨rkyilmaz et al, 2010
[71]
3.2 mg/dl 0.4 3.3 0.5 NS NR
Ulusoy et al, 2010 [72] 3.54 mg/dl 0.56 3.57 0.46 NS NR
Polynutrient supplement
Brouwers et al, 2002
[37]
Baseline CIS: 51.4









Jammes et al, 2011
[42]
3.92 mmol/l 0.12 3.99 0.08 NS NR
Kim et al, 2011 [46] 75 μg/g 25–219 (95%
CI)
56 23–138 NS NR
Norregaard et al, 1994
[59]
3.25 mmol/l (median) NR 3.9 NR NS NR






1410 378–5200 p = .013 NR
Selenium
Eisinger et al, 1997
[39]
83 ng/ml 17 87 12 NS NR
(Continued )
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concentrations of vitamin E were lower in patients compared to controls (patients n = 162,
controls n = 140; pooled SMD:-1.57, 95%CI:-3.09,-0.05; p = .042). No differences were found
in patients compared to controls in circulating concentrations of vitamin C (patients n = 124,
controls n = 132; pooled SMD:-0.55, 95%CI:-1.38,0.28; p = .19), vitamin D (patients n = 871,
controls n = 1039; pooled SMD:-0.17, 95%CI:-0.41,0.06; p = .15), and vitamin D deficiency
(patients n = 435, controls n = 604; pooled OR:0.23, 95%CI:-0.54,0.99; p = .17). There were no
differences between patients and controls in circulating concentrations of the minerals calcium
(patients n = 620, controls n = 518; pooled SMD:-0.15, 95%CI:-0.50,0.19; p = .38), and magne-
sium (patients n = 218, controls n = 148; pooled SMD:-0.59, 95%CI:-1.33,0.15; p = .12). All
analyses revealed substantial to considerable heterogeneity in the effect sizes, as can be found
in Fig 2.
Table 4. (Continued)
Kim et al, 2011 [46] 75 μg/g 25–219 (95%
CI)
56 23–138 NS NR
Reinhard et al, 1998
[64]
Median: 70.8 μg/l 67.7–75.3
(95%CI)
76.8 73.4–81.6 p<.05 NR
Study Patients Controls Statistically
significant
Linked to clinical parameter
Mean SD Mean SD
















Sendur et al, 2008 [69] 44.4 μg/dl 12.1 38.7 13.9 NS FIQ Pearson’s correlation coefficient:
0.011 (NS)
Sodium
Jammes et al, 2011
[42]
138 mmol/l 0.5 140 0.4 NS NR
Kim et al, 2011 [46] 78 μg/g 31–195 (95%
CI)
72 27–195 NS NR






1700 510–4790 NS NR
Zinc
Eisinger et al, 1997
[39]
16.9 mmol/l 1.8 16.1 1.9 NS NR
Khalifa et al, 2016 [45] 75.87 μg/dL 5.5 93.21 11.94 p<.05 NR
Kim et al, 2011 [46] 167 μg/g 120–232
(95%CI)
165 125–217 NS NR
La Rubia et al, 2013
[48]
66.48 ng/ml 18.82 106.8 22.41 p<.001 PCS-12 Pearson’s correlation coefficient:
0.402 (p = .017)
Maes et al, 2006 [51] 73.5 mg/dl NR 87 NR p = .0001 Fibrofatigue scale Pearson’s correlation
coefficient: -0.039 (NS)

















Sendur et al, 2008 [69] 102.8 μg/dl 24.7 77.2 31 p = .001 FIQ Pearson’s correlation coefficient:
-0.106 (NS)
CI = confidence interval, CIS = checklist individual strength, FIQ = fibromyalgia impact questionnaire, FIQR = revised fibromyalgia impact questionnaire,
NR = not reported, NS = not significant, PCS = physical component summary, SD = standard deviation, VAS = visual analogue scale, x = reported in meta-
analyses.
https://doi.org/10.1371/journal.pone.0176631.t004
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Subgroup analyses. Subgroup analyses were performed including studies with more than
half the maximum study quality score (>9 quality points), if more than three studies with a
sufficient quality score were available. The additional analysis was not possible for magnesium,
since only two studies achieved more than half of the maximum quality score. No differences
in circulating concentrations of vitamin C (patients n = 93, controls n = 102, pooled SMD:-
Fig 2. Forest plots of studies investigating vitamins. (A) Vitamin C; (B) Vitamin D; (C) Vitamin D
deficiency (<20ng/ml); (D) Vitamin E.
https://doi.org/10.1371/journal.pone.0176631.g002
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0.78, 95CI:-1.95, 0.39; p = .19) [32,42,43,67], vitamin D (patients n = 358, controls n = 376,
pooled SMD:-0.07, 95%CI:-0.44,0.30; p = .71) [35,49,61,65,70–72], vitamin D deficiency
(patients n = 121, controls n = 130; pooled OR:-0.12, 95%CI:-1.24,1.01; p = .84) [49,61,65,70],
and calcium = (patients n = 184, controls n = 178; pooled SMD:0.18 95%CI:-0.18,0.54; p = .34)
[49,61,71,72] were found. The significant difference in circulating concentrations of vitamin
E between patients and controls disappeared when studies with low quality score were
excluded (patients n = 91, controls n = 90, pooled SMD: -1.86, 95%CI:-4.28, 0.56; p = .13)
[32,67,73].
Subgroup analyses were performed separately for the syndromes, when more than three
studies were available per syndrome. Since vitamin D, vitamin D deficiency and calcium were
only determined in FMS patients, additional subgroup analyses were possible for vitamin C,
vitamin E and magnesium. No statistically significant difference between patients and controls
was found in the three studies investigating circulating concentrations of vitamin C in FMS
patients (patients n = 101, controls n = 100; pooled SMD:0.14, 95%CI:-0.16,0.44; p = .32).
However, the heterogeneity was substantially lower (I2 = 13.3% versus 88.5% in the overall
analysis including CFS patients), indicating a high consistency of studies’ results. The signifi-
cant difference in circulating concentrations of vitamin E between patients and controls disap-
peared when the single CFS study was excluded (patients n = 141, controls n = 120; pooled
SMD:-0.95, 95%CI:-2.41,0.50; p = .20. Lastly, no considerable differences were found in analy-
ses of the five studies investigating circulating concentrations of magnesium in FMS patients
(patients n = 203, controls n = 133; pooled SMD:-0.51, 95%CI:-1.34,0.32; p = .23).
Publication bias. Finally, we tested whether publication bias could have affected the
results. Corresponding funnel plots can be found in Fig 4. Egger’s test showed that there was
significant funnel plot asymmetry in vitamin E (p = .039), with no significant asymmetry
among the other analyses. Trimming was performed in the calcium studies using the Trim and
Fig 3. Forest plots of studies investigating minerals. (A) Calcium; (B) Magnesium.
https://doi.org/10.1371/journal.pone.0176631.g003
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Fill test, and the contour-enhanced funnel plot revealed two added studies in the statistically
significant areas. No studies were trimmed or filled among the vitamin C, vitamin D, vitamin
D deficiency, vitamin E, and magnesium studies, indicating absence of substantial publication
bias.
Fig 4. Funnel plots. (A) Vitamin C; (B) Vitamin D; (C) Vitamin D deficiency (<20ng/ml); (D) Vitamin E; (E) Calcium; (F) Magnesium.
https://doi.org/10.1371/journal.pone.0176631.g004
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Discussion
We found little evidence to support our hypothesis that vitamin and mineral deficiencies play
a role in the pathophysiology of both CFS and FMS, or that the use of nutritional supplements
is effective in these patients. Poor study quality and considerable heterogeneity in most studies
was found, which makes it difficult to reach a final conclusion. Consistent significant lower cir-
culating concentrations were found repeatedly and in the majority of studies for vitamin A
and vitamin E in patients compared to controls. However, the significant difference in circulat-
ing concentrations of vitamin E between patients and controls disappeared when excluding
low quality studies. None of these or other vitamins and minerals have been repeatedly or con-
sistently linked to clinical parameters. In addition, RCTs testing supplements containing these
vitamins and/or minerals did not result in clinical improvements.
This review has several strengths. First, this is the first review focusing on vitamin and min-
eral deficiencies among CFS and FMS patients. We were able to give a clear overview of the
current knowledge existing in literature. Second, we included only studies that examined CFS
and FMS patients according to the official diagnostic criteria. We therefore have included rela-
tively homogeneous groups of patients. Third, because we defined strict in- and exclusion cri-
teria, e.g. patients should meet the official diagnostic criteria, or clinical cohorts must have an
appropriate control group, poor quality studies were filtered out. Nevertheless, the vast major-
ity of the included studies scored a quality score below a reasonable study quality. Fourth,
enough studies that investigated similar vitamins or minerals were available, which made it
possible to conduct six meta-analyses. Lastly, we had no language restrictions for the included
abstracts or full text articles, which enabled us to include all relevant articles.
We must acknowledge that this study also has its limitations, which are mostly due to limi-
tations in original studies on which this review was based. First, most studies were observa-
tional in nature. In general, observational studies have a lower validity than RCTs, and they are
more susceptible to bias (e.g. selection and information bias) and confounding factors. Poten-
tial confounders were assessed in about half of the studies, but almost no studies adjusted their
analyses for potential confounders. Consequently, the results of the current review may be
affected by the methodological weaknesses that are accompanied by the observational study
designs. Second, quality assessment revealed a poor study quality in the majority of studies.
This demonstrates that substantial improvements can be made in terms of study quality, espe-
cially in specification of in- and exclusion criteria, presenting disease characteristics of the par-
ticipants, making use of validated methods to assess vitamin and mineral status, to perform
the vitamin and mineral assessments in duplicate, and, as mentioned earlier, to adjust analyses
for potential confounders. Furthermore, a quality issue in research on CFS and FMS patients
is that of careful selection of control groups. Our quality assessment showed that many
included studies fell short because of the selection of the controls, which could result in inaccu-
rate study results. Third, a problem that affects the validity of meta-analyses is the presence of
publication bias. Funnel plots indicated the absence of publication bias in the majority of the
meta-analyses. Trimming was performed among the calcium studies, and two “missing” stud-
ies were added, while no significant funnel plot asymmetry was present. However, trimming
was performed in the statistically significant areas, which argues against the presence of publi-
cation bias. Although Egger’s test is preferred for more than 10 studies, it revealed significant
funnel plot asymmetry in vitamin E, while no trimming was performed. It is therefore possible
that the significant outcomes of vitamin E in patients are influenced by publication bias. Lastly,
a substantial to considerable heterogeneity in most studies was found, which makes it difficult
to reach a final conclusion about vitamin status in CFS and FMS patients.
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This review reveals that very few RCTs have investigated the effect of vitamin and mineral
supplementation versus placebo in CFS and FMS patients. Most published RCTs found no
treatment effect of vitamin and mineral supplementation on clinical parameters. So, the evi-
dence for beneficial effects of supplementation in CFS and FMS patients is not proportional to
the large quantity of supplements that are used by these patients. Nevertheless, the industry of
vitamin and minerals supplements is increasing, for example, Americans spend an estimated
$36.7 billion each year on supplements [77]. This is important information, since the vitamins
and minerals in these products are sometimes supplemented in doses high enough to cause
side effects, for example gastric discomfort, insomnia, dizziness or weakness [17]. The vast
majority of available studies concerned FMS patients. Several FMS studies investigated vitamin
D, whereas most CFS studies have focused on vitamin E. Only one CFS study that investigated
vitamin E was suitable for inclusion in the meta-analysis. It is remarkable that the significant
difference of vitamin E between patients and controls disappeared when the single CFS study
was excluded in the sensitivity analysis, while the studies that were not suitable for inclusion in
the meta-analysis reported significant lower vitamin E concentrations in particularly CFS
patients versus controls. Further research is needed to determine whether this may indicate
that vitamin E levels are lower in CFS patients, but not in FMS patients. This systematic review
and meta-analysis provides no further insights in whether the remaining vitamins and miner-
als differ between these two medical conditions.
We conclude that there is little evidence to support the hypothesis that vitamin and mineral
deficiencies play a role in the pathophysiology of both CFS and FMS. Furthermore, the current
literature on vitamins and minerals in CFS and FMS is of poor quality and stresses the need
for well-performed intervention research, and large population-based and age-matched pro-
spective studies in CFS and FMS, in order to gain more insight in the role of vitamins and min-
erals in the pathophysiology of CFS and FMS. According to our results, potential vitamins and
minerals that should be further examined include vitamin A and vitamin E.
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